G. Chouinard

Publications301
h-index53
Citations12,003
Highly Influential Citations349
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • G. Fava
  • 649 Publications, 19,232 Citations
  • L. Annable
  • 114 Publications, 3,387 Citations
  • D. Greenblatt
  • 1,284 Publications, 53,520 Citations
  • P. Seeman
  • 480 Publications, 38,885 Citations
  • Publications
  • Influence
Manual for the Extrapyramidal Symptom Rating Scale (ESRS)
The Extrapyramidal Symptom Rating Scale (ESRS) was developed to assess four types of drug-induced movement disorders (DIMD): Parkinsonism, akathisia, dystonia, and tardive dyskinesia (TD).… Expand
  • 315
  • 38
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.
BACKGROUND In two double-blind trials conducted in North America, 513 patients with chronic schizophrenia received risperidone, haloperidol, or placebo. In the present study, combined data from the… Expand
  • 607
  • 32
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
BACKGROUND Approximately 50% of patients with schizophrenia or schizoaffective disorder attempt suicide, and approximately 10% die of suicide. Study results suggest that clozapine therapy… Expand
  • 1,042
  • 23
  • PDF
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
In a double-blind study, 135 inpatients with a diagnosis of chronic schizophrenia were randomly assigned to 8 weeks of treatment with one of six parallel treatments: risperidone (a new central… Expand
  • 790
  • 21
Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.
  • G. Chouinard
  • Psychology, Medicine
  • The Journal of clinical psychiatry
  • 1 March 2004
Low and medium potency benzodiazepines were initially introduced for the treatment of insomnia and anxiety. Their therapeutic actions as anxiolytics, sedative hypnotics, anticonvulsants, and muscle… Expand
  • 254
  • 12
Severe cases of neuroleptic-induced supersensitivity psychosis: Diagnostic criteria for the disorder and its treatment
  • G. Chouinard
  • Psychology, Medicine
  • Schizophrenia Research
  • 1 July 1991
Tardive dyskinesia is thought to result from neostriatal dopaminergic receptor supersensitivity induced by chronic treatment with neuroleptics. Similarly, receptor supersensitivity occurring in other… Expand
  • 98
  • 12
  • PDF
Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder.
BACKGROUND Anecdotal evidence suggests patients with obsessive-compulsive disorder (OCD) are treated with selective serotonin uptake inhibitors at dosages significantly higher than those used with… Expand
  • 218
  • 11
Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): Cross-scale comparison in assessing tardive dyskinesia
Assessing tardive dyskinesia (TD) has been complicated by the use of different research criteria and rating scales. We studied concordance between two commonly used scales, the Abnormal Involuntary… Expand
  • 98
  • 11
Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study.
The efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) once-daily monotherapy in generalized anxiety disorder (GAD) was assessed. This multicentre, double-blind,… Expand
  • 121
  • 9
  • PDF
Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.
Tardive dyskinesia is thought to result from neostriatal dopaminergic receptor supersensitivity induced by chronic treatment with neuroleptics. The authors suggest that dopaminergic supersensitivity… Expand
  • 257
  • 7
  • PDF